Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Affimed N.V.
Industry Sector: HealthTechnology
CEO: Shawn M. Leland, PharmD
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -0.16
Exchange/Ticker 1: NASDAQ:AFMD
Exchange/Ticker 2: N/A
Latest Market Cap: $8,679,700
BioCentury | Oct 24, 2024
Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
BioCentury | Oct 18, 2024
Management Tracks
Hoess succeeds Crawford at ViaNautis
Plus: Korenberg now CFO of Palvella and updates from Moffitt and CHMP
BioCentury | Feb 2, 2024
Management Tracks
New CFOs for Sanofi, Takeda
Plus: NextPoint names Eisai vet Cheung CEO, Love joins Gilead board and updates from Acumen, Maxion, EnteroBiotix, Remix
BioCentury | Jan 9, 2024
Management Tracks
Germano succeeds Starr as Sage chair
Plus: CEO changes at Xoma, Affimed, and updates from ArriVent, Calliditas, Prime, Caribou, Janux and Insitro
BioCentury | Jan 6, 2024
Management Tracks
Management moves abound on eve of JPM, including new chairs for Sobi, Corteria
Plus: Zaderej to retire as AxoGen CEO and updates from AxoGen, Delfi, Illumina, Evozyne, Kiyatec, Sosei, Twist, Novocure, Be Bio, Novo Holdings, Bioluminescence and more
BioCentury | Dec 13, 2022
Product Development
Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava
Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more
BioCentury | Dec 7, 2022
Product Development
ASH22 could be IL-18’s watershed moment
CAR T data at ASH could trigger more development in one of oncology’s less crowded cytokine spaces
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
BioCentury | Nov 4, 2022
Deals
Nov. 4 Quick Takes: Bayer returns rights to Ionis’ antithrombotic
Plus Vicore gains on IPF data and updates from Acrivon, BioAtla, Novadip and more
BioCentury | Nov 4, 2022
Regulation
Nov. 3 Quick Takes: FDA delay could shorten Apellis’ lead in geographic atrophy
Plus NextCure abandons SIGLEC15 and updates from Emalex, Moderna, Aurinia, Affimed, Artiva and more
Items per page:
1 - 10 of 67